• CytoSorbents to implement a 1-for-20 reverse stock split, effective Sept. 8, 2026.
• Shares to trade on a split-adjusted basis at the Sept. 8 market open under CTSO.
• Move targets Nasdaq’s $1 minimum bid-price rule for continued listing.
• Outstanding share count expected to drop to about 3,151,101 from 63,022,020, excluding rounding effects.
• Options and warrants to be adjusted proportionately, including exercise prices.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytoSorbents Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609030700PR_NEWS_USPR_____NY39807) on September 03, 2026, and is solely responsible for the information contained therein.